@Article{096504019X15509372008132,
AUTHOR = {Yueming He,
 Wang Sheng,
 Weiguo Hu,
 Jing Lin, Junjun Liu, Bing Yu, 
Xinru Mao, Lu Zhang, Jin Huang, Guangsuo Wang},
TITLE = {Different Types of <i>ROS1</i> Fusion Partners Yield Comparable  Efficacy to Crizotinib},
JOURNAL = {Oncology Research},
VOLUME = {27},
YEAR = {2019},
NUMBER = {8},
PAGES = {901--910},
URL = {http://www.techscience.com/or/v27n8/48619},
ISSN = {1555-3906},
ABSTRACT = {<i>ROS1</i> rearrangements define a distinct molecular subset of non-small-cell lung cancer (NSCLC), which can be 
treated effectively with crizotinib, a tyrosine kinase inhibitor (TKI) targeting <i>ROS1/MET/ALK</i> rearrangements. 
Diverse efficacy was observed in <i>ROS1</i>-rearranged NSCLC patients. Because of its rareness, very limited 
studies have investigated the correlation between different fusion partners and response to crizotinib. In this 
study, we retrospectively screened 6,235 advanced NSCLC patients (stage IIIB to IV) from five hospitals and 
identified 106 patients with <i>ROS1</i> rearrangements based on either plasma or tumor tissue testing using capturebased targeted sequencing. The most frequently occurring fusion partners included cluster of differentiation 74 
(CD74), ezrin (EZR), syndecan 4 (SDC4), and tropomyosin 3 (TPM3), occurring in 49.1%, 17%, 14.2%, and 
4.7% of patients, respectively. Among them, 38 patients were treated with crizotinib. Seventeen patients were 
treatment naive, and the remaining were previously treated with pemetrexed-based chemotherapy. Collectively, 
there was no significant difference among patients with various types of <i>ROS1</i> fusion partners in overall survival (OS) and progression-free survival (PFS). Patients who were treated with crizotinib as first-line therapy 
showed comparable PFS (p=0.26) to patients who were previously treated with pemetrexed-based chemotherapy. For treatment-naive patients, patients with low baseline <i>ROS1</i> allelic fraction (AF) had a statistically 
significant longer OS than those with high <i>ROS1</i> AF (184 vs. 110 days, <i>p</i>=0.048). Collectively, our study 
demonstrates that <i>ROS1</i><sup>+</sup>
 patients with various fusion partners show comparable efficacy to crizotinib.},
DOI = {10.3727/096504019X15509372008132}
}